Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Pre-publication versions of this article are available by contacting email@example.com.
|28 Jul 2015||Submitted||Original manuscript|
|24 Sep 2015||Reviewed||Reviewer Report - Martin Haag|
|25 Sep 2015||Reviewed||Reviewer Report - Jiejie Xu|
|26 Oct 2015||Author responded||Author comments - Jifang gong|
|Resubmission - Version 2|
|26 Oct 2015||Submitted||Manuscript version 2|
|4 Nov 2015||Reviewed||Reviewer Report - JIN LI|
|11 Nov 2015||Reviewed||Reviewer Report - Jiejie Xu|
|4 Dec 2015||Author responded||Author comments - Jifang gong|
|Resubmission - Version 3|
|4 Dec 2015||Submitted||Manuscript version 3|
|15 Jan 2016||Author responded||Author comments - Jifang gong|
|Resubmission - Version 4|
|15 Jan 2016||Submitted||Manuscript version 4|
|28 Jan 2016||Editorially accepted|
|8 Feb 2016||Article published||10.1186/s12885-016-2092-9|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.